Abbott Labs' (ABT) Aveir DR has received US approval - TD Cowen
Tweet Send to a Friend
TD Cowen analyst Joshua Jennings reiterated an Outperform rating and $130.00 price target on Abbott Labs (NYSE: ABT), noting that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


